Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Mental Disorders, Mental Health Services
Interventions: Cognitive behavior therapy for work success (CBTw); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Solid Tumor
Interventions: ZL-1211; Drug
Lead sponsor: Zai Biopharmaceutical (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more

Conditions: Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
Interventions: JNJ-64264681, JNJ-67856633; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Extracorporeal Photochemotherapy With Transimmunization; Procedure
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMT-162; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more

Conditions: Breast Cancer
Interventions: Epidiferphane, Taxane Chemotherapy; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Interventions: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more

Conditions: Healthy
Interventions: SYNB1934, SYNB1618; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept; Genetic · Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 25 Years to 89 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more

Conditions: Healthy Volunteers
Interventions: Branebrutinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Healthy
Interventions: Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid; Drug · Dietary Supplement
Lead sponsor: Carsten Skarke, MD; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: JNJ-42165279, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hypoalbuminemia
Interventions: Specimen collection; Procedure
Lead sponsor: Akron Children's Hospital; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Mantua, Ohio

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin degludec, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 146
States / cities: Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: Obesity
Interventions: AMG 786, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Tustin, California • Aventura, Florida • Miami, Florida

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: Batiraxcept, Cabozantinib (Cabo), Nivolumab; Drug
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 13 more

Conditions: Lung Transplant Infection
Interventions: Tolsura; Drug
Lead sponsor: Hong Nguyen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer
Interventions: FP-1305 (bexmarilimab); Biological
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Solid Tumors
Interventions: M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 9
States / cities: Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more

Conditions: Cervical Carcinoma, Endometrial Carcinoma, Malignant Female Reproductive System Neoplasm, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Interventions: DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Coronado, California • Montclair, California • Panorama City, California + 12 more

Conditions: Malignant Melanoma
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 1 more

Search by objective public record fields.

Cognitive Behavior Therapy for Work Success in Veterans With Mental Illness: A Pre-post Efficacy Study

A Study of ZL-1211 in Patients With Advanced Solid Tumor

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

A Study of Modified mRNA Vaccines in Healthy Adults

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma